Tyra Biosciences Posts Q3 2026 Results, Raises $400M for Cancer Drug Push
Tyra Biosciences shared early Phase 2 data for dabogratinib and secured $400M in new financing, extending its cash runway through 2030.
Tyra Biosciences reported its third-quarter 2026 financial results alongside key clinical and operational developments, including the first Phase 2 data readout for its lead drug candidate and a sizable capital raise that stretches the company's financial horizon by several years.
The company disclosed initial Phase 2 results from its SURF302 trial, evaluating oral dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle-invasive bladder cancer, known as IR NMIBC. The readout marks a significant milestone for a drug the company is advancing under what it calls a 3x3 strategy — a framework targeting multiple indications across the FGFR3 pathway.
Read more M&T Bank Raises Quarterly Dividend 20% to $1.80 Per Share →
To fund that broader ambition, Tyra completed a $400 million financing round during the quarter. The capital infusion gives the biotech a cash runway through 2030, encompassing cash, cash equivalents, and marketable securities, providing the company with the financial stability to pursue multiple clinical programs simultaneously without near-term dilution pressure.
The combination of early efficacy signals in bladder cancer and a bolstered balance sheet positions Tyra as a closely watched name in the oncology biotech space, particularly among investors tracking FGFR-targeted therapies. Bladder cancer represents a high-unmet-need market where few oral targeted options currently exist for lower-risk disease settings.
Analysts and investors will likely scrutinize the granular SURF302 data as Tyra moves dabogratinib further through development, with the 2030 runway suggesting management anticipates multiple trial readouts and potential regulatory interactions before needing additional capital. Continue reading at Earnings.